Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Indolent Non-Hodgkin Lymphoma × ibrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 111 Lymphoma, Mantle-Cell 60 Lymphoma, Large B-Cell, Diffuse 34 Waldenstrom Macroglobulinemia 28 Lymphoma, Follicular 28 Lymphoma, Non-Hodgkin 26 Lymphoma 26 Recurrence 22 Lymphoma, B-Cell 20 Lymphoma, B-Cell, Marginal Zone 18 Neoplasms 13 Leukemia 13 Leukemia, B-Cell 10 Leukemia, Lymphoid 8 Multiple Myeloma 7 Burkitt Lymphoma 7 Bronchiolitis Obliterans Syndrome 7 Leukemia, Myeloid, Acute 6 Hematologic Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Leukemia, Hairy Cell 3 Hodgkin Disease 3 Hematologic Diseases 3 Graft vs Host Disease 3 Carcinoma, Non-Small-Cell Lung 3 Neoplasms, Plasma Cell 2 Myelodysplastic Syndromes 2 Melanoma 2 Lymphoproliferative Disorders 2 Lymphatic Diseases 2

Interventions

obinutuzumab 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689869 2021-05-07

Alternative

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Indolent Non-Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡